8-KRegulation FDExhibits & Filings

MCKESSON CORP 8-K Report, Regulation FD Disclosure (Dec 10, 2012)

Filed December 10, 2012For Securities:MCK

Summary

McKesson Corporation (MCK) filed an 8-K on December 10, 2012, to disclose a regulatory development concerning its proposed acquisition of PSS World Medical, Inc. The company, along with PSS World Medical, issued a joint press release indicating that McKesson has voluntarily withdrawn and re-filed its notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. This action is a procedural step often taken to address inquiries or concerns from antitrust regulators, potentially to allow for further review and facilitate the approval process. This filing is important for investors as it signals potential delays or continued scrutiny in the acquisition process of PSS World Medical. While the re-filing itself does not inherently mean the deal is in jeopardy, it suggests that regulatory authorities are actively reviewing the transaction. Investors should monitor subsequent filings and announcements for updates on the antitrust review and the expected closing date of the acquisition.

Key Highlights

  • 1McKesson (MCK) announced a procedural update regarding its acquisition of PSS World Medical, Inc.
  • 2McKesson voluntarily withdrew and re-filed its Hart-Scott-Rodino Act notification.
  • 3This action is related to the ongoing antitrust review of the proposed acquisition.
  • 4The filing includes a joint press release from McKesson and PSS World Medical dated December 10, 2012.
  • 5The information is furnished under Regulation FD and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
  • 6Investors should closely monitor further developments in the antitrust review process.

Frequently Asked Questions

The primary purpose of this 8-K filing is to inform investors that McKesson Corporation has voluntarily withdrawn and re-filed its notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. This is a procedural step related to the antitrust review of McKesson's proposed acquisition of PSS World Medical, Inc.

Not necessarily. While the re-filing suggests that antitrust regulators may have had questions or required additional time for review, it is a common practice in merger and acquisition processes. It indicates continued engagement with regulators rather than an outright blockage of the deal.

The Hart-Scott-Rodino (HSR) Act requires parties to certain mergers and acquisitions to notify the Federal Trade Commission (FTC) and the Department of Justice (DOJ) and to wait a specified period before closing the transaction. This allows the agencies to review the proposed transaction for potential antitrust concerns.

Investors should look for further announcements or filings from McKesson regarding the progress of the antitrust review. Updates on clearance from regulatory bodies or any potential adjustments to the deal timeline or terms would be significant.